Background: Melanoma is a rare but serious skin cancer that is responsible for >90% of skin cancer-related deaths. This retrospective data analysis quantifies the direct cost of medical care by disease stage at diagnosis for patients with metastatic melanoma. Methods: The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was queried for patients diagnosed between 2004-2009 with stage IIIB/C and stage IV (M1a, M1b, M1c) melanoma. The primary outcome was overall medical utilization and associated costs from diagnosis to death, the end of Medicare enrolment, or 12/31/2010. Results are stratified by disease stage at diagnosis and presented as per-patient per-month (PPPM) costs. Results: Of the 1263 patients meeting the study criteria (mean age: 75 years; 64% male, 92% white, mean duration of follow up: 37.5 months), 66.6% were diagnosed at stage IIIB/C and 33.4% at stage IV. Cost of care increased with disease stage. Total PPPM costs ranged from $1966 for patients diagnosed with stage IIIB to $4585 among patients diagnosed with stage M1c. Outpatient costs accounted 48.9% of total medical costs among stage IIIB patients, and 38.7% of total medical costs for stage M1c patients. Inpatient costs accounted for 37.1% (stage M1b) -40.9% (stage M1c) of total medical costs. Conclusions: Healthcare costs for treating patients with metastatic melanoma increase by disease stage. The cost of care was more than double among patients with late stage compared to those with early stage. Treatments demonstrating ability to prevent disease progression from early stage to late stage may confer an economic benefit among other clinical advantages.
Introduction
Melanoma is a rare but serious skin cancer that can rapidly infiltrate deep, vascular skin layers, and it commonly metastasizes very early [1] [2] . Although melanoma affects people of all ages, 34% of patients are younger than 55 years at diagnosis [3] . Among people with metastatic melanoma, survival data from real-world clinical practice consistently show that survival differs greatly by stage of disease [4] [5] . In a study of patients with metastatic melanoma from the Surveillance, Epidemiology, and End Results (SEER) database, patients with unresectable (no curative resection was performed) non visceral disease (stages IIIB or IIIC or M1a) had a median overall survival (OS) of 22 to 24 months [5] . Those with distant metastasis to the lung (stage M1b)-with or without skin or subcutaneous metastases-had a median OS of 11 months [5] . The poorest survival duration was observed in patients with metastases to other visceral sites (stage M1c), who had a median OS of 5 months [5] .
Melanoma is a devastating disease with economic implications for individuals, their families, and society. A systematic review by Guy and colleagues found that medical costs were higher among patients diagnosed with late-stage melanoma compared to those diagnosed at early-stage disease [6] . However, these studies either used very old data (e.g., SEER-Medicare 1991 -1996 and 1999 -2003 , were based on very small sample sizes, or conducted outside the US. Few recent studies have quantified the direct healthcare costs by disease stage accrued by patients diagnosed with metastatic melanoma. One of the reasons for lack of studies on costs by disease stage in metastatic melanoma is that insurance medical claims databases usually do not have accurate disease stage information while melanoma registry databases do contain stage information but often do not have healthcare resource use and cost information. This study describes the medical utilization and costs of patients with metastatic melanoma by stage of disease from the payer's perspective, using more recent SEER-Medicare data that had information on both cost and disease stage in the US. Stage of disease was based on the American Joint Committee on Cancer (AJCC) 6 th edition staging system [7] .
Methods

Data Sources
This analysis utilized two linked data sources: the SEER cancer registry and Medicare claims. The SEER database is a unique population-based cancer registry containing cancer staging at the time of diagnosis and survival time for residents in 18 geographic areas in the US, representing 26% of the nation's population [8] . 
Study Population
The study population comprised patients diagnosed with stage IIIB, IIIC, or IV 
Outcomes
All-cause medical utilization and direct costs were captured during the follow-up period. Utilization was measured as the presence of at least one claim for the following service types: inpatient admissions, skilled nursing facilities 
Statistical Analyses
Descriptive analyses were conducted to examine patient characteristics and mean direct medical costs. Total costs and costs by place of service are reported for each stage at diagnosis. Means and standard deviations were computed for continuous variables while proportions were computed for categorical variables.
Statistical significance testing was conducted among disease stages, with ANOVA tests on continuous variables and Chi-squared tests on proportions.
Results
From (Figure 1 ). of total costs, while inpatient admissions accounted for 36.1% -40.9% of total costs. As there appeared to be similar utilization across stage for most service types when evaluating the proportion of patients with at least one claim, it is possible that the substantial increase in costs across stages reflects more frequent contact with the healthcare system or more involved in intensive care.
Discussion
Other published analyses have examined healthcare costs of patients with melanoma in the US. A systematic review by Guy and colleagues in 2012 examined 19 publications from 1990 to 2011 [6] . Despite variations in the populations studied and the costing approach used, they found that medical costs were higher among patients diagnosed with late-stage melanoma compared to those diagnosed at early-stage disease [6] .
Two of the US analyses identified by Guy, et al. [6] presented costs by phase of across all disease stages [12] . Costs were highest for patients diagnosed at stage III and stage IV disease during the initial phase ($2594 and $2541, respectively) [12] . Costs stratified by venue of service (i.e., inpatient, outpatient, SNF, HHC)
were not reported [12] .
Yabroff and colleagues conducted a similar analysis using SEER-Medicare data from 1999 to 2003 and defined phase differently: initial (first 12 months after diagnosis), continuing (months between initial and last phases), and last (last 12 months of life) [13] . The researchers compared cancer patients to non-cancer patients to determine net costs of melanoma in 2004 US $ [13] . Like Seidler, et al., [12] Yabroff, et al. reported that the net cost of care was highest in the last year of life, and net costs in all phases were higher for patients with distant metastases than those with localized disease (initial = $21,717 vs. $3211; last = $46,177 vs. $20,145) [13] .
The systematic review by Guy, et al. [6] , also identified four U.S. for stage T4a melanoma, and $110,150 for stage T4b melanoma [15] . Hillner and colleagues examined the procedures for 100 patients with metastatic melanoma from 1997-1998 and projected that total average cost per patient was $59,400, more than 60% of which was for inpatient care [16] .
The study most directly comparable to the analysis presented here was conducted by Davis and colleagues using SEER-Medicare data from 1991-2005 [17] .
Davis, et al., also found that healthcare costs of patients with melanoma increase with advanced stage and that hospital services were the main cost driver [17] .
They reported that the costs for patients with stage IV melanoma were substantially higher ($11,471) than costs for patients with stage IIIA/B ($3395) or IIIC ($6885) [17] . Although they used older data, their cost estimate for stage IV is much higher than the estimates reported in our study [17] . One potential explanation is that Davis, et al., removed patients with HMO insurance [17] while about one-third of our study population was enrolled in an HMO. When HMO 
Conclusion
Healthcare costs for treating patients with metastatic melanoma increase by disease stage. The cost of care was more than double among patients with late stage compared to those with early stage. Treatments demonstrating ability to prevent disease progression from early stage to late stage may confer an economic benefit among other clinical advantages.
